Lunai Bioworks Inc. Common Stock (LNAI)

FairStock Score: 34/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable earnings, honest capital allocation, and a margin of safety. Lunai Bioworks does not yet meet that standard. It is a pre-clinical biotech developing dendritic-cell vaccines and a BioSymetrics platform. In fiscal 2026, the year ended 2026-06-30, it reported revenue of just $51,992 and a net loss of $3.6 million, or diluted EPS of -$1.06. Fiscal 2025 produced a net loss of $178.0 million and diluted EPS of -$86.27, while fiscal 2024 lost $88.4 million. Recent quarters are uneven: fiscal Q3 2026, the quarter ended 2026-03-31, had revenue of $20,942 and a net loss of $2.6 million; fiscal Q2 2026 lost $1.8 million; fiscal Q1 2026 showed net income of $2.8 million. Free cash flow over the trailing twelve months was -$5.3 million, a -48.5% FCF yield against the $10.8 million market cap. FairStock’s Piotroski score is 3/9 and Altman Z is -74.73, signs of financial fragility. At the 2026-10-13 close of $1.03, FairStock’s P/E is negative and P/B is not meaningful. A pre-clinical company has no moat in my view; its value depends on trial outcomes, regulatory decisions, and financing. The 52-week range of $0.15 to $5.02 shows speculation, not steady compounding. Without profits, revenue growth, or a reliable balance sheet, I cannot call this cheap on Graham terms. It is a lottery ticket on science.

In plain English: Lunai Bioworks is a tiny pre-clinical biotech working on cancer vaccines and a data platform. The business looks weak today: it has almost no sales, loses money, and burns cash. At $1.03, the price is hard to call cheap or fair because there are no profits to compare against, and the stock looks more like a bet on future medical results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2026 10-Q (period ended 2025-12-31) · fiscal Q1 2026 10-Q (period ended 2025-09-30) · fiscal Q3 2025 10-Q (period ended 2025-03-31) · FY2026 10-K (period ended 2026-06-30) · FY2025 10-K (period ended 2025-06-30) · FY2024 10-K (period ended 2024-06-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer